

Media release 3/04

Straumann Board appoints Oskar Ronner as Vice Chairman

The Board of Directors of Straumann Holding AG today announced the appointment of Oskar Ronner as Vice Chairman of the Board and Head of the Compensation Committee. Mr Ronner, a Member of the Board since 2000, takes over his new responsibilities from Thomas Straumann, who has decided to relinquish these roles in order to support his growing business commitments in other industries. As the company's major shareholder, Mr. Straumann will continue to play an active role on the Board, having been re-elected with Dominik Ellenrieder for a further three-year term by the shareholders' AGM on 23 April 2004.

Chairman Rudolf Maag commented: "Oskar Ronner's wealth of business experience gained from his participation on the Boards of large Swiss companies, in addition to his proven track record as CEO of several prestigious international corporations, more than qualify him for these new roles and we are glad that he has accepted to take them on. We are also greatly indebted to Thomas Straumann for his many contributions to shaping our company over the past years and are pleased that he will continue to play an important part on the Board and as our major shareholder".

Straumann's Board of Directors is therefore composed as follows:

Rudolf Maag, Chairman, Finance and Audit Committee (Chair),
Oskar Ronner, Vice Chairman, Compensation Committee (Chair),
Dr Sebastian Burckhardt, Finance and Audit Committee,
Dominik Ellenrieder, Compensation Committee,
Jürg Morant, Finance and Audit Committee,
Thomas Straumann, Compensation Committee.

Further details of Board activities, Members' CVs and Corporate Governance at Straumann can be found in the current edition of the Group's Annual Report, which is available online at www.straumann.com or on request from the Company.

Disclaimer

This release contains certain "forward-looking statements", which can be identified by the use of terminology such as "to support," "qualify," "to take on," "will continue," or similar wording. Such forward-looking statements reflect the current views of members of the Board/management and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Group to differ materially from those expressed or implied. Should one or more of these risks or uncertainties materialize either partially or fully, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Waldenburg, 11 May 2004

Contacts:

Straumann Corporate Communications
(+41) 061 965 1111

Straumann is a global leader in oral implantology. In collaboration with the International Team for Implantology (ITI), leading clinics, research institutes and universities, the Group develops, produces and distributes implants and instruments in addition to providing services for dental implant specialists worldwide. Straumann successfully entered the field of dental tissue regeneration through the acquisition of Kuros Therapeutics AG and Biora AB. Straumann implants and instruments are manufactured in Switzerland, whilst its dental tissue regeneration products are produced in Sweden. With affiliates in 14 countries and distributors in 35, Straumann employs more than 900 people worldwide and generated sales of CHF 344 million in 2003.

Straumann Holding AG, Hauptstrasse 26, CH- 4427 Waldenburg
Telephone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01
E-Mail: investor.relations@straumann.com or info@straumann.com
Homepage: www.straumann.com
